-
Study aim
-
The results of this study indicate the clinical implications of treatment modalities of moderate carpal tunnel syndrome, and it is undoubtedly important to prove these differences clinically, enabling researchers to employ more appropriate therapeutic approaches than the economic burden imposed. Reduce the burden on society and patients and provide the least complications and best outcomes for patients.
-
Design
-
A concealed, randomized, open-label, sham-controlled clinical trial with a parallel-group design of 126 patients.
-
Settings and conduct
-
Patients are referred daily to Imam Reza Clinic of Poursina Hospital and if they have the inclusion criteria, 42 patients in each group will be enrolled in the study based on randomized block design with a total of 126 patients. Patients will be randomly divided into three treatment groups.
-
Participants/Inclusion and exclusion criteria
-
Patients with unilateral or bilateral CTS will be enrolled.
Patients will be excluded if they have a history of wrist surgery, polyneuropathy, brachial plexopathy or thoracic outlet syndrome, history of thrombocytopenia, platelet disorder, systemic infection, pregnancy, and rheumatologic disorders, previous injection of cortisone for the treatment of CTS, Thenar muscle atrophy.
-
Intervention groups
-
Control group: The control group will be given splint with a painkiller (meloxicam 15 mg) and vitamin B1. Group 2, 40 mg methylprednisolone (Depo-Medrol) in combination with 1% lidocaine will be injected.
Group 3 in order to laser therapy, the patient in a supine position will be irradiated to an area of 4 x 5 cm area around the nerve. The scanner laser will be illuminated from a distance of 10 cm.
-
Main outcome variables
-
Pain severity; Distal sensory delay; Distal motor delay; Symptom severity scale; Functional status scale; complications.